|
|
|
11-50 employees
View all
|
|
Biotechnology
|
|
266 Second Ave, Waltham, Massachusetts 02451, US
|
|
Palleon Pharmaceuticals is the leading biotechnology company focused on developing Glyco-Immune Checkpoint inhibitors to treat cancer.
The company’s proprietary Convergence Platform integrates technologies and insights from world-renowned scientific leaders in the fields of glycoscience and human immunology to create a novel approach to treating cancer. By targeting multiple immune cell types, Glyco-Immune Checkpoint inhibitors will tackle resistance to first-generation immuno-oncology agents, and make possible a wider range of rational combination therapies to treat cancer. While Palleon is focused primarily on oncology, the Convergence Platform is applicable to other therapeutic areas including infectious diseases, neurodegeneration, inflammation, and fibrosis.
The company is advancing its pipeline and development programs with a $47.6 million Series A financing from leading biotech venture investors SR One, Pfizer Ventures, Vertex Ventures HC, Takeda Ventures, and AbbVie Ventures.
|
Palleon Pharmaceuticals Email Formats | Example Email Formats | Percentage |
---|---|---|
{f}{last} | [email protected] |
75.00%
|
The widely used Palleon Pharmaceuticals email format is {f}{last} (e.g. [email protected]) with 75.00% adoption across the company.
To contact Palleon Pharmaceuticals customer service number in your country click here to find.
Jim Broderick is the CEO of Palleon Pharmaceuticals. To contact Jim Broderick email at [email protected]. Or you may call +1.7819748300
Find accurate personal emails, work emails and phone numbers for employees
Accelerate prospecting with instant access to 300M professionals from 30M companies with the right contact details.